CN1079954A - 喷雾冷冻的萘丁酮和其生产方法 - Google Patents

喷雾冷冻的萘丁酮和其生产方法 Download PDF

Info

Publication number
CN1079954A
CN1079954A CN93100940A CN93100940A CN1079954A CN 1079954 A CN1079954 A CN 1079954A CN 93100940 A CN93100940 A CN 93100940A CN 93100940 A CN93100940 A CN 93100940A CN 1079954 A CN1079954 A CN 1079954A
Authority
CN
China
Prior art keywords
spray chilling
naphthalene butanone
butanone
naphthalene
sheet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN93100940A
Other languages
English (en)
Inventor
G·S·伦纳德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of CN1079954A publication Critical patent/CN1079954A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/255—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coating By Spraying Or Casting (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Freezing, Cooling And Drying Of Foods (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Road Signs Or Road Markings (AREA)
  • Catching Or Destruction (AREA)

Abstract

具有比先前可能的体积小的、喷雾冷冻的和配制 成单位剂量形式的萘丁酮。

Description

本发明涉及喷雾冷冻的萘丁酮（nabumetone）和其生产方法。
GB  1，474，377描述了一种通常被称为萘丁酮的非甾族抗炎药4-（6-甲氧基-2-萘基）-丁-2-酮。该专利还描述了萘丁酮的生产方法。
萘丁酮最通常是作为500  mg或1000  mg吞咽片开处方。合成的含有萘丁酮和常规赋形剂的片剂体积相当大，对一些病人可能引起吞咽困难。
常规分离和碾磨过的萘丁酮的松装密度范围为0.35-0.39g/cm3，摇实密度范围为0.44-0.48g/cm3，当与常规的赋形剂混合后产生的片剂体积对于500 mg萘丁酮片为0.485 cm3，对于1000 mg萘丁酮片为0.970 cm3。
常规分离和碾磨过的萘丁酮通过与常规填料、表面活性剂和崩解剂混合而配制成常规的吞咽片。现已发现可与赋形剂，尤其是填料相混合的药物最大量是82%。进一步增大药物的百分比（即降低赋形剂，尤其是填料的百分比）引起片剂在生产、储存和转运过程中易于碎裂，这是一个很明显的缺点。
喷雾冷冻是一种已存在大约30多年的先有技术，已被用于生产食品如咖啡以及药品。
通常选择喷雾冷冻，是因为该方法产生均一的产品质量如粒度、含湿量和堆密度。
在药品生产中使用喷雾冷冻法，是因为该方法可以提供具有改进的流动特性的产品。
现已发现，喷雾冷冻的萘丁酮具有优良的配制特性，生产便宜，出人意料地可以用比先前需要的量少的赋形剂配制成可行的片剂。此外，喷雾冷冻过的萘丁酮具有意想不到的优点，它比常规分离和碾磨过的萘丁酮更密实，因此，可被配制成较小的易吞咽的片剂。
因此，本发明提供了喷雾冷冻的萘丁酮。
本发明进一步提供了松装密度范围为0.40-0.65g/cm3的喷雾冷冻的萘丁酮。
具体地讲，喷雾冷冻的萘丁酮的松装密度范围适宜地为0.45-0.60g/cm3，或更优选地是0.5-0.55g/cm3，最优选地约为0.5g/cm3。
本发明也提供了摇实密度范围为0.50-0.65g/cm3的喷雾冷冻的萘丁酮。
具体地讲，喷雾冷冻的萘丁酮的摇实密度适宜为0.54-0.62g/cm3，或更优选地为0.58-0.62g/cm3，最优选地约为0.60g/cm3。
本发明也提供了含有与可药用的载体混合的喷雾冷冻的萘丁酮的药物组合物。
应该理解，下文所用的赋形剂一词是指可药用载体。
本发明的另一方面提供了单位剂量形式的喷雾冷冻的萘丁酮。合适的单位剂量形式包括用制剂学领域中已知的常规技术形成的含萘丁酮的片剂、香囊、悬浮剂和栓剂。
本发明还提供了含500 mg与常规赋形剂混合的喷雾冷冻的萘丁酮的吞咽片，该片剂的体积为0.429 cm3。因此本发明提供了含500 mg喷雾冷冻的萘丁酮的吞咽片，该片的体积小于0.480cm3，优选小于0.450 cm3，最优选地小于0.430 cm3。
本发明还提供了含1000mg与常规赋形剂混合的喷雾冷冻的萘丁酮的吞咽片，该片剂的体积为0.858cm3。因此本发明提供了含1000mg喷雾冷冻的萘丁酮的吞咽片，该片的体积小于0.960 cm3，优选小于0.930cm3，最优选地小于0.860 cm3。
本发明还提供了不用或基本上不用常规填充剂作赋形剂制备的喷雾冷冻的萘丁酮的单位剂量制剂。
应该理解，填充剂是制剂学领域中通常承认的那些填充剂，例如，微晶纤维素、羟丙甲基纤维素、乳糖和淀粉。
本发明还提供了常规吞咽片，该片剂中喷雾冷冻的萘丁酮对赋形剂的百分比（w/w）大于82%，适宜是大于85%，更适宜的是大于88%，最好大于90%。
本发明的另一方面提供了制备喷雾冷冻的萘丁酮的方法，该方法包括，熔化固体萘丁酮，将之喷雾到喷雾冷冻器的冷冻室中，收集形成的产品。
优选地是将萘丁酮加热至高过其熔点（80℃）20℃使之熔化。
熔化后的萘丁酮以16-17kg/hr的速度送入冷冻室比较适宜。
冷冻室冷却至1-4℃比较适宜。
萘丁酮适宜地是通过2个流体喷嘴送入冷冻室，用热的压缩空气喷成雾状。形成的产品适宜地是收集在旋风收集器中。
上面所用的喷雾冷冻器适宜地是常规的市售的喷雾冷冻器。
用于喷雾冷冻的萘丁酮适宜地是按照在EP-A-003074（Beecham  Group  plc）或EP-A-0288144（Beecham  Group  plc）中概述的方法制备，但应该理解，用任何合适的手段制备的萘丁酮均可用于喷雾冷冻。
先前已有描述，萘丁酮可用于治疗炎症，特别是由风湿性关节炎或骨关节炎引起的那些炎症、扭伤、劳损、癌症痛、发热、骨质疏松症和肌筋膜痛综合征。因此，本发明提供了一种治疗炎症、扭伤、劳损、癌症痛、发热、骨质疏松症和肌筋膜痛综合征的方法，该方法包括使需要该治疗的患者服用有效量的喷雾冷冻的萘丁酮。
本发明还提供了喷雾冷冻的萘丁酮在生产用于治疗炎症、扭伤、劳损、癌症痛、发热、骨质疏松症和肌筋膜痛综合征的药物中的应用。
本发明还提供了用于治疗炎症、扭伤、劳损、癌症痛、发热、骨质疏松症和肌筋膜痛综合征的药物组合物，其中包含与可药用载体混合的喷雾冷冻的萘丁酮。
下列实施例描述喷雾冷冻的萘丁酮的制备和分别含500mg和1000mg萘丁酮的吞咽片的形成。
实施例1
喷雾冷冻的萘丁酮的制备
将按EP-A-0003074中所述方法制备的萘丁酮熔化（80℃）并保持在大约100℃。然后用蠕动泵以16-17kg/hr的进料速度经2个流体（空气喷雾）喷嘴将熔体送入常规喷雾冷冻器的冷冻室中，在此用热的压缩空气在80  psi（要求国际单位）进行雾化。
然后当喷雾过的萘丁酮喷雾到保持在1-4℃的冷冻室中时将之冷却，用旋风收集器收集结晶产品。
上面所用的喷雾冷冻器是Drytech  Ltd，46  Morley  Road，Tonbridge，Kent，UK的市售产品。
实施例2（500  mg喷雾冷冻的萘丁酮吞咽片）
将下列诸组分按常规方法混合，并压缩成吞咽片。
500  mg  喷雾冷冻的萘丁酮
25mg  ＊Explotab
2  mg  月桂基硫酸钠
527mg
实施例3（1000  mg喷雾冷冻的萘丁酮吞咽片）
将下列诸成分按常规方法混合，并压缩成吞咽片。
1000mg  喷雾干燥的萘丁酮
50mg  ＊Explotab
4  mg  月桂基硫酸钠
1027mg
＊  淀粉乙醇酸钠的商标。

Claims (12)

1、制备喷雾冷冻的萘丁酮的方法，其中包括熔化固体萘丁酮，把它喷雾到喷雾冷冻器的冷冻室中，收集形成的产品。
2、根据权利要求1的方法，其中喷雾冷冻的萘丁酮的松装密度范围为0.40-0.65g/cm3。
3、根据权利要求1的方法，其中喷雾冷冻的萘丁酮的摇实密度范围为0.50-0.65g/cm3。
4、制备药物组合物的方法，其中包括将按权利要求1的方法制备的喷雾冷冻的萘丁酮与可药用的载体混合。
5、根据权利要求4的方法，其中含有按照权利要求1制备的喷雾冷冻的萘丁酮的药物组合物为单位剂量形式。
6、根据权利要求5的方法，其中单位剂量形式是含500 mg与赋形剂混合的、按权利要求1的方法制备的喷雾冷冻的萘丁酮的吞咽片，该片的体积小于0.480 cm3。
7、根据权利要求5的方法，其中单位剂量形式是含1000mg与赋形剂混合的、按权利要求1的方法制备的喷雾冷冻的萘丁酮的吞咽片，该片的体积小于0.960 cm3。
8、根据权利要求5-7中任一项的方法，其中单位剂量形式没有或基本上没有填充剂作赋形剂。
9、根据权利要求6-8中任一项的方法，其中吞咽片中按照权利要求1制备的喷雾冷冻的萘丁酮对赋形剂的百分比（w/w）大于82%。
10、根据权利要求7的方法，其中吞咽片中喷雾冷冻的萘丁酮对赋形剂的百分比大于90%。
11、治疗炎症、扭伤、过劳、癌症痛、发热、骨质疏松症和肌筋膜痛综合征的方法，其中包括使需要此种治疗的患者服用有效量的权利要求1-10中任一项的喷雾冷冻的萘丁酮。
12、权利要求1-10中任一项的喷雾冷冻的萘丁酮在生产用于治疗炎症、扭伤、劳损、癌症痛、发热、骨质疏松症和肌筋膜痛综合征的药物中的应用。
CN93100940A 1992-01-29 1993-01-28 喷雾冷冻的萘丁酮和其生产方法 Pending CN1079954A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9201857.1 1992-01-29
GB929201857A GB9201857D0 (en) 1992-01-29 1992-01-29 Novel compound

Publications (1)

Publication Number Publication Date
CN1079954A true CN1079954A (zh) 1993-12-29

Family

ID=10709436

Family Applications (1)

Application Number Title Priority Date Filing Date
CN93100940A Pending CN1079954A (zh) 1992-01-29 1993-01-28 喷雾冷冻的萘丁酮和其生产方法

Country Status (24)

Country Link
US (1) US5539000A (zh)
EP (1) EP0624087B1 (zh)
JP (1) JPH07503245A (zh)
KR (1) KR950700056A (zh)
CN (1) CN1079954A (zh)
AT (1) ATE150298T1 (zh)
AU (1) AU3362693A (zh)
BG (1) BG98933A (zh)
BR (1) BR9305674A (zh)
CA (1) CA2129027A1 (zh)
CZ (1) CZ182894A3 (zh)
DE (1) DE69309037T2 (zh)
DK (1) DK0624087T3 (zh)
ES (1) ES2099419T3 (zh)
FI (1) FI943550A0 (zh)
GB (1) GB9201857D0 (zh)
GR (1) GR3023142T3 (zh)
HU (1) HUT67462A (zh)
IL (1) IL104526A0 (zh)
MX (1) MX9300430A (zh)
NO (1) NO942813L (zh)
SK (1) SK91694A3 (zh)
WO (1) WO1993014747A1 (zh)
ZA (1) ZA93577B (zh)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
GB9920148D0 (en) * 1999-08-25 1999-10-27 Smithkline Beecham Plc Novel composition
TWI262791B (en) 1999-10-27 2006-10-01 Nobex Corp 6-methoxy-2-naphthylacetic acid prodrugs
US6552078B2 (en) 1999-10-27 2003-04-22 Nobex Corp 6-methoxy-2-naphthylacetic acid prodrugs
US6436990B1 (en) 1999-10-27 2002-08-20 Nobex Corporation 6-methoxy-2-naphthylacetic acid prodrugs
US20020132010A1 (en) * 2000-12-22 2002-09-19 Yihong Qui Divalproex sodium dosage forms and a process for their production
US20040161474A1 (en) * 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
US20060083791A1 (en) * 2002-05-24 2006-04-20 Moerck Rudi E Rare earth metal compounds methods of making, and methods of using the same
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
BRPI0417338A (pt) * 2003-12-04 2007-04-17 Pfizer Prod Inc formas de dosagem de azitromicina multiparticulada por processos a base de lìquido
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
CA2547597A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate compositions with improved stability
JP2007513147A (ja) * 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 押し出し機を使用して、好ましくはポロキサマーとグリセリドを含有する多粒子結晶性医薬組成物を製造するための噴霧凝結方法
SI1691787T1 (sl) * 2003-12-04 2008-10-31 Pfizer Prod Inc Postopek za pripravo farmacevtskih produktov iz več delcev
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
BRPI0416535A (pt) * 2003-12-04 2007-01-09 Pfizer Prod Inc processo de congelamento por vaporização empregando um extrusor para preparar composições de azitromicina de multiparticulado contendo preferivelmente um poloxámero e um glicerìdeo
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
EP1809305A4 (en) * 2004-10-15 2009-12-30 Altairnano Inc PHOSPHATE BINDER WITH REDUCED TABLET LOAD
AU2006279343A1 (en) * 2005-08-17 2007-02-22 Altairnano, Inc. Treatment of chronic renal failure and other conditions in domestic animals: compositions and methods
US8436051B2 (en) 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository
US7541384B2 (en) * 2007-06-08 2009-06-02 Axcan Pharma Inc. Mesalamine suppository
US8217083B2 (en) * 2007-06-08 2012-07-10 Aptalis Pharma Canada Inc. Mesalamine suppository
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
CA3224506A1 (en) 2010-05-12 2011-11-17 Unicycive Therapeutics, Inc. Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
EP3544614A4 (en) 2016-11-28 2020-08-05 Lipocine Inc. ORAL TESTOSTERONE UNDECANOATE THERAPY

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4420639C1 (en) * 1973-09-11 2001-08-21 Beecham Group Ltd Aromatic compounds
GB1474377A (en) 1973-09-11 1977-05-25 Beecham Group Ltd Naphthalene derivatives
US4086346A (en) * 1974-04-06 1978-04-25 Bayer Aktiengesellschaft Preparation of melt-sprayed spherical phenacetin granules
DE3833446A1 (de) 1988-10-01 1990-04-05 Hoechst Ag Verfahren zur herstellung von arzneimittelwirkstoff-partikeln mit verbesserten fliess-, lager- und formulierungseigenschaften sowie arzneimittel, die diese arzneimittelwirkstoff-partikeln enthalten

Also Published As

Publication number Publication date
FI943550A (fi) 1994-07-28
CZ182894A3 (en) 1995-02-15
DE69309037T2 (de) 1997-07-24
FI943550A0 (fi) 1994-07-28
BG98933A (en) 1995-07-28
CA2129027A1 (en) 1993-08-05
NO942813D0 (no) 1994-07-28
GR3023142T3 (en) 1997-07-30
ATE150298T1 (de) 1997-04-15
ES2099419T3 (es) 1997-05-16
NO942813L (no) 1994-07-28
AU3362693A (en) 1993-09-01
IL104526A0 (en) 1993-05-13
SK91694A3 (en) 1995-03-08
EP0624087A1 (en) 1994-11-17
KR950700056A (ko) 1995-01-16
JPH07503245A (ja) 1995-04-06
EP0624087B1 (en) 1997-03-19
DK0624087T3 (da) 1997-09-01
ZA93577B (en) 1994-01-13
WO1993014747A1 (en) 1993-08-05
DE69309037D1 (de) 1997-04-24
GB9201857D0 (en) 1992-03-18
BR9305674A (pt) 2005-01-11
US5539000A (en) 1996-07-23
HUT67462A (en) 1995-04-28
MX9300430A (es) 1994-08-31
HU9402221D0 (en) 1994-09-28

Similar Documents

Publication Publication Date Title
CN1079954A (zh) 喷雾冷冻的萘丁酮和其生产方法
US5854291A (en) Pain reliever and method of use
Bengnér et al. Increasing incidence of forearm fractures: a comparison of epidemiologic patterns 25 years apart
CN1198625C (zh) 用于治疗粘膜炎、口炎和贝赫切特综合征的药物组合物
CN1571670A (zh) 弗利班西林在治疗性障碍中的用途
CN1466461A (zh) 止痒性组合物和促进创伤治愈的组合物
CN1840154A (zh) 一种治疗白脉病的软膏剂及制备方法
CN1105561A (zh) 治疗酗酒不适的治疗组合物及其使用方法
WO1993009766A1 (en) Method for treatment of acute and chronic painful arthropathic conditions in human and other mammals
CN1103339C (zh) 药用级泥炭黄腐植酸钠的制备方法
CN108904542A (zh) 用于抑菌修复的手性超分子水凝胶皮肤软膏的制备方法
US7910136B2 (en) Nutritional supplement for osteoarthritis
AU673724B2 (en) Wound-healing compositions containing iodine and a non-reducing sugar
US5278172A (en) Method and composition for treating tendon or joint inflammation using a vasodilator
CN1742741A (zh) 含氨基葡萄糖和钙剂及维生素d的药物组合物及其应用
CN1165011A (zh) 治疗风湿病的外用膏药
EP2292218B1 (en) Topical application of nimesulide and thiocolchicoside
CA2471151A1 (en) Calcium l-threonate for preventing or treating cartilage related diseases
CN1234374C (zh) 一种治疗***的药膏
CN1084185C (zh) 一种治疗口腔和咽喉疾病的液体喷雾剂
CN1473568A (zh) 用于治疗感冒的含有布洛芬的药物组合物
CN1449797A (zh) 复方陈香胃片及其制备方法
CN115969902B (zh) 用于治疗寻常型银屑病的药物及其制备方法
KR20100111061A (ko) 상처 치료용 조성물
RU2201757C1 (ru) Средство профилактики и лечения дегенеративно-дистрофических изменений суставов и способ его получения

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication